Relx (NYSE:RELX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.
Separately, Redburn Atlantic assumed coverage on shares of Relx in a research note on Wednesday, January 8th. They set a “buy” rating for the company.
View Our Latest Analysis on Relx
Relx Price Performance
Institutional Investors Weigh In On Relx
Several large investors have recently modified their holdings of RELX. FMR LLC raised its stake in shares of Relx by 8.3% during the 3rd quarter. FMR LLC now owns 7,148,837 shares of the technology company’s stock worth $339,284,000 after acquiring an additional 548,423 shares in the last quarter. Bank of America Corp DE boosted its holdings in Relx by 4.2% during the fourth quarter. Bank of America Corp DE now owns 6,246,462 shares of the technology company’s stock worth $283,714,000 after buying an additional 253,107 shares in the last quarter. Lazard Asset Management LLC boosted its holdings in Relx by 1.2% during the fourth quarter. Lazard Asset Management LLC now owns 4,224,334 shares of the technology company’s stock worth $191,868,000 after buying an additional 48,793 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Relx by 4.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,189,886 shares of the technology company’s stock worth $144,885,000 after acquiring an additional 121,831 shares during the period. Finally, Ameriprise Financial Inc. raised its position in Relx by 368.7% during the fourth quarter. Ameriprise Financial Inc. now owns 2,807,038 shares of the technology company’s stock worth $127,437,000 after acquiring an additional 2,208,119 shares during the period. Institutional investors own 15.02% of the company’s stock.
About Relx
RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.
Recommended Stories
- Five stocks we like better than Relx
- Which Wall Street Analysts are the Most Accurate?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- Financial Services Stocks Investing
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- What is diluted earnings per share (Diluted EPS)?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.